Systems modeling: A pathway to drug discovery

Current Opinion in Chemical Biology

Volumn 9, Issue 4, 2005, Pages 400-406

  Rajasethupathy, Priyamvada ^a   Vayttaden, Sharat J ^a   Bhalla, Upinder S ^a  

^a TATA INSTITUTE OF FUNDAMENTAL RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; BORTEZOMIB; CYCLOOXYGENASE 2 INHIBITOR; INFLIXIMAB; INTERLEUKIN 5 ANTIBODY; LIGAND; PYRAZINAMIDE; RECEPTOR; ROFECOXIB; SILDENAFIL; TRASTUZUMAB;

ANGIOGENESIS; ARTHRITIS; ASTHMA; BIOLOGY; CARDIOVASCULAR DISEASE; CELL COMMUNICATION; CLINICAL TRIAL; COMPUTER MODEL; COMPUTER SYSTEM; DIABETES MELLITUS; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDUSTRY; DRUG MECHANISM; DRUG TARGETING; HEART INFARCTION; HUMAN; MATHEMATICAL ANALYSIS; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; METABOLISM; MYELOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN INTERACTION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TUBERCULOSIS; VISUAL DISORDER;

ANIMALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; SIGNAL TRANSDUCTION; SYSTEMS THEORY;

EID: 22544454480     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2005.06.008     Document Type: Review

References (48)

1. G. Apic, T. Ignjatovic, S. Boyer, and R.B. Russell Illuminating drug discovery with biological pathways FEBS Lett 579 2005 1872 1877
2. E.C. Butcher, E.L. Berg, and E.J. Kunkel Systems biology in drug discovery Nat Biotechnol 22 2004 1253 1259
3. B.M. Rao, D.A. Lauffenburger, and K.D. Wittrup Integrating cell-level kinetic modeling into the design of engineered protein therapeutics Nat Biotechnol 23 2005 191 194
4. K. Lundstrom Structural genomics of GPCRs Trends Biotechnol 23 2005 103 108
5. R.J. Filion, and A.S. Popel Intracoronary administration of FGF-2: a computational model of myocardial deposition and retention Am J Physiol Heart Circ Physiol 288 2005 H263 H279
6. K. Forsten-Williams, C.C. Chua, and M.A. Nugent The kinetics of FGF-2 binding to heparan sulfate proteoglycans and MAP kinase signaling J Theor Biol 233 2005 483 499
7. M. Simons, B.H. Annex, R.J. Laham, N. Kleiman, T. Henry, H. Dauerman, J.E. Udelson, E.V. Gervino, M. Pike, and M.J. Whitehouse Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial Circulation 105 2002 788 793
8. H.S. Wiley, S.Y. Shvartsman, and D.A. Lauffenburger Computational modeling of the EGF-receptor system: a paradigm for systems biology Trends Cell Biol 13 2003 43 50
9. J. Baselga, and C.L. Arteaga Critical update and emerging trends in epidermal growth factor receptor targeting in cancer J Clin Oncol 23 2005 2445 2459
10. B.S. Hendriks, L.K. Opresko, H.S. Wiley, and D. Lauffenburger Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels J Biol Chem 278 2003 23343 23351
11. B. Goldstein, J.R. Faeder, and W.S. Hlavacek Mathematical and computational models of immune-receptor signalling Nat Rev Immunol 4 2004 445 456
12. P.J. Woolf, and J.J. Linderman An algebra of dimerization and its implications for G-protein coupled receptor signaling J Theor Biol 229 2004 157 168
13. U.S. Bhalla, and R. Iyengar Emergent properties of networks of biological signaling pathways Science 283 1999 381 387
14. H. Kitano Computational systems biology Nature 420 2002 206 210
15. J.M. Haugh, A. Wells, and D.A. Lauffenburger Mathematical modeling of epidermal growth factor receptor signaling through the phospholipase C pathway: mechanistic insights and predictions for molecular interventions Biotechnol Bioeng 70 2000 225 238
16. A. Wells Tumor invasion: role of growth factor-induced cell motility Adv Cancer Res 78 2000 31 101
17. A. Hoffmann, A. Levchenko, M.L. Scott, and D. Baltimore The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation Science 298 2002 1241 1245 This is an excellent example of how modeling and experimental studies complement each other to advance a field. Their predictive NF-κB model has inspired many studies in cancer, apoptosis and other clinically relevant systems. Sung et al. [18] have adapted this model to explore alternative drug targets and treatment schedules in the NF-κB pathway for cancer therapy.
18. M.H. Sung, and R. Simon In silico simulation of inhibitor drug effects on nuclear factor-kappaB pathway dynamics Mol Pharmacol 66 2004 70 75
19. J.J. Saucerman, L.L. Brunton, A.P. Michailova, and A.D. McCulloch Modeling beta-adrenergic control of cardiac myocyte contractility in silico J Biol Chem 278 2003 47997 48003 This study integrates both the electrical and chemical signals in a cell, and uses network properties of the β-AR signaling system to arrive at optimal sites for drug intervention.
20. R. Christopher, A. Dhiman, J. Fox, R. Gendelman, T. Haberitcher, D. Kagle, G. Spizz, I.G. Khalil, and C. Hill Data-driven computer simulation of human cancer cell Ann N Y Acad Sci 1020 2004 132 153 This cancer cell simulation is one of the largest and most detailed models in the literature. The authors have explored the connectivity of signal transduction pathways with gene-expression networks, in silico and in vivo, in unicellular and multicellular systems. The model has undergone extensive validation steps through multiple iterations between experiments and simulations. Using the model, the authors are in a position to test drug efficacy, most importantly, in a patient-specific manner; in line with the ideal of personalized medicine.
21. S. Helfert, A.M. Estevez, B. Bakker, P. Michels, and C. Clayton Roles of triosephosphate isomerase and aerobic metabolism in Trypanosoma brucei Biochem J 357 2001 117 125
22. J. Marin-Garcia, and M.J. Goldenthal Heart mitochondria signaling pathways: appraisal of an emerging field J Mol Med 82 2004 565 578
23. M. Aimar-Beurton, B. Korzeniewski, T. Letellier, S. Ludinard, J.P. Mazat, and C. Nazaret Virtual mitochondria: metabolic modelling and control Mol Biol Rep 29 2002 227 232
24. S. Cortassa, M.A. Aon, E. Marban, R.L. Winslow, and B. O'Rourke An integrated model of cardiac mitochondrial energy metabolism and calcium dynamics Biophys J 84 2003 2734 2755
25. T.D. Vo, H.J. Greenberg, and B.O. Palsson Reconstruction and functional characterization of the human mitochondrial metabolic network based on proteomic and biochemical data J Biol Chem 279 2004 39532 39540
26. A. Bugrim, T. Nikolskaya, and Y. Nikolsky Early prediction of drug metabolism and toxicity: systems biology approach and modeling Drug Discov Today 9 2004 127 135
27. M.C. Kowala, C.E. Mazzucco, K.S. Hartl, S.M. Seiler, G.A. Warr, S. Abid, and R.I. Grove Prostacyclin agonists reduce early atherosclerosis in hyperlipidemic hamsters. Octimibate and BMY 42393 suppress monocyte chemotaxis, macrophage cholesteryl ester accumulation, scavenger receptor activity, and tumor necrosis factor production Arterioscler Thromb 13 1993 435 444
28. S. Moncada, R. Gryglewski, S. Bunting, and J.R. Vane An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation Nature 263 1976 663 665
29. D. Salvemini, K. Seibert, J.L. Masferrer, T.P. Misko, M.G. Currie, and P. Needleman Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation J Clin Invest 93 1994 1940 1947
30. P. Wlodawer, and B. Samuelsson On the organization and mechanism of prostaglandin synthetase J Biol Chem 248 1973 5673 5678
31. S. Goto, H. Bono, H. Ogata, W. Fujibuchi, T. Nishioka, K. Sato, and M. Kanehisa Organizing and computing metabolic pathway data in terms of binary relations Pac Symp Biocomput 1997 175 186
32. A.R. Kansal Modeling approaches to type 2 diabetes Diabetes Technol Ther 6 2004 39 47
33. H. Kitano, K. Oda, T. Kimura, Y. Matsuoka, M. Csete, J. Doyle, and M. Muramatsu Metabolic syndrome and robustness tradeoffs Diabetes 53 Suppl 3 2004 S6 S15 This paper is of particular interest because the authors discuss a very novel approach to treat diabetes, an age-old disorder. This model spans multiple cell types and signaling pathways and shows that it might be better to target properties of a system (robustness) rather than single molecules. This is an interesting perspective that shows the power and relevance of systems modeling in therapeutics, and can be extended to other robust systemic diseases such as cancer and AIDS.
34. C.J. Musante, A.K. Lewis, and K. Hall Small- and large-scale biosimulation applied to drug discovery and development Drug Discov Today 7 2002 S192 S196
35. M.J. Leckie, A. ten Brinke, J. Khan, Z. Diamant, B.J. O'Connor, C.M. Walls, A.K. Mathur, H.C. Cowley, K.F. Chung, and R. Djukanovic Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response Lancet 356 2000 2144 2148
36. R.L. Winslow, S. Cortassa, and J.L. Greenstein Using models of the myocyte for functional interpretation of cardiac proteomic data J Physiol 563 2005 73 81
37. J.B. Bassingthwaighte, and K.C. Vinnakota The computational integrated myocyte: a view into the virtual heart Ann N Y Acad Sci 1015 2004 391 404
38. P. Hunter, N. Smith, J. Fernandez, and M. Tawhai Integration from proteins to organs: the IUPS Physiome Project Mech Ageing Dev 126 2005 187 192
39. T.L. Blundell, H. Jhoti, and C. Abell High-throughput crystallography for lead discovery in drug design Nat Rev Drug Discov 1 2002 45 54
40. B.J. Druker, and N.B. Lydon Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia J Clin Invest 105 2000 3 7
41. S.K. Chanda, and J.S. Caldwell Fulfilling the promise: drug discovery in the post-genomic era Drug Discov Today 8 2003 168 174
42. R. Kramer, and D. Cohen Functional genomics to new drug targets Nat Rev Drug Discov 3 2004 965 972
43. I. Yeh, T. Hanekamp, S. Tsoka, P.D. Karp, and R.B. Altman Computational analysis of Plasmodium falciparum metabolism: organizing genomic information to facilitate drug discovery Genome Res 14 2004 917 924
44. M. Cascante, L.G. Boros, B. Comin-Anduix, P. de Atauri, J.J. Centelles, and P.W. Lee Metabolic control analysis in drug discovery and disease Nat Biotechnol 20 2002 243 249
45. A.S. Perelson Modelling viral and immune system dynamics Nat Rev Immunol 2 2002 28 36
46. H. van de Waterbeemd, and E. Gifford ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov 2 2003 192 204
47. G.S. Mack Can complexity be commercialized? Nat Biotechnol 22 2004 1223 1229
48. M. Hucka, A. Finney, H.M. Sauro, H. Bolouri, J.C. Doyle, H. Kitano, A.P. Arkin, B.J. Bornstein, D. Bray, and A. Cornish-Bowden The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models Bioinformatics 19 2003 524 531